Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Interval Assessment Trial of Lu177-Dotatate Every 8 Versus Every 16 Weeks in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (NETs) to Lower TOxicity

NCT06878664 is registered in ClinicalTrials.gov with Grupo Espanol de Tumores Neuroendocrinos as lead sponsor.

NCT NCT06878664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06878664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Interval Assessment Trial of Lu177-Dotatate Every 8 Versus Every 16 Weeks in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (NETs) to Lower TOxicity
Lead sponsor
Grupo Espanol de Tumores Neuroendocrinos
Phase
Phase 3
Overall status
Recruiting
Start date
June 12, 2025
Completion date
January 31, 2029
Enrollment
166 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

grade1-2 advanced midgut neuroendocrine tumors (nets)